New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study of Thio, a telomere-targeting agent sequenced with Regeneron Inc.’s immune checkpoint inhibitor, Libtayo (cemiplimab), as a third-line treatment for advanced non-small-cell lung cancer (NSCLC) showed median overall survival of 16.9 months for the 22 NSCLC patients who received at least one dose of Thio in parts A and B.
C the Signs Ltd. recently received a capital injection of $8 million from Khosla Ventures to expand its AI-powered cancer prediction platform to the U.S. market.
Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of hepatocellular carcinoma and hepatitis B.
One of the proteins required for centrosome clustering is kinesin family member C1 (KIFC1/HSET), and modulation of KIFC1 stability could reduce its activity in cancer cells.
Researchers at the University of California at San Francisco have identified an RNA-binding protein that increased the translation of Myc mRNA. The authors wrote that their work, which was published online in Nature Cell Biology on Feb. 4, 2025, “transforms the understanding of the translational code in cancer and illuminates therapeutic openings to target the expression of oncogenes.” Myc is a transcription factor that regulates multiple cellular growth factors. Its overexpression is a driver event in many solid tumors, including pancreatic cancer. Drugging Myc, though, has so far proved challenging.
Mesenchymal-epithelial transition factor (MET) plays a relevant role in growth, survival, migration and tissue repair. Alterations in MET have been found in non-small-cell lung cancer and head and neck cancer, and are associated with aggressive and difficult-to-treat cancer types.
Tiumbio Co Ltd. has described bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of cancer, fibrosis, diabetes, metabolic syndrome, and renal and inflammatory disorders.
Nutshell Biotech (Shanghai) Co. Ltd. has identified eukaryotic translation initiation factor 4E (eiF4E) inhibitors reported to be useful for the treatment of cancer.
Forkhead box protein L2 (FOXL2) is a protein involved in ovary development and maintenance, among other functions. Mutations in its gene are involved in ovarian failure and granulosa cell tumors, being the latter a rare cancer type caused in most cases by the C134W mutation (c.402C>G) in the FOXL2 gene. By using CRISPR/Cas9 technology, researchers from Spain have aimed to remove this mutation in the FOLX2 gene from granulosa tumor cells.
RSS
